Joint project of the International Network of Agencies for Health Technology Assessment -: Part 2:: Managing the diffusion of positron emission tomography with health technology assessment

被引:6
作者
Adams, EJ [1 ]
Almazán, C
Morland, B
Bradbury, I
King, R
Rheinberger, P
机构
[1] VA Boston Healthcare Syst 11T, Vet Adm Technol Assessment Program, Boston, MA 02130 USA
[2] Catalan Agcy Hlth Technol Assessment & Res, Hlth Serv Assessment, Barcelona 08023, Spain
[3] Norwegian Knowledge Ctr Hlth Serv, N-0030 Oslo, Norway
[4] Univ Ulster, Coleraine BT62 1SA, Londonderry, North Ireland
[5] So Hlth Victoria, Program Med, Monash Med Ctr, E Bentleigh, Australia
[6] Natl Assoc Statutory Hlth Insurance Phys, Dept Hlth Technol Assessment, D-10623 Berlin, Germany
关键词
positron emission tomography; tomography emission computed; technology assessment; health policy; diffusion of innovation;
D O I
10.1017/S0266462306050951
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: Since 1997, members of the International Network of Agencies for Health Technology Assessment (INAHTA) have collaborated on a Joint Project to track the diffusion, evaluation, and clinical policy of positron emission tomography (PET). Part 2 of this updated Joint Project report summarizes HTA-based strategies for directing the clinical use of PET and a discussion on the value of HTA in managing the diffusion of high cost diagnostic technologies, which were presented at an INAHTA-sponsored workshop at the Health Technology Assessment International Annual Meeting in 2004 on strategies for managing high cost diagnostic technologies. Methods: A summary of the workshop proceedings is presented. Conclusions: Sharing assessment work, universal agreement in assessment conclusions, stakeholder input, and modeling techniques help manage the uncertainty in the evidence base while targeting clinical use of PET toward the most promising indications. Emphasis on HTA findings, linkage between financing of clinical PET and outcome evaluation, and targeted dissemination of scientific findings empower providers to reduce unnecessary utilization and contain costs within a quality improvement framework. Above all, a trustworthy source of HTA information and a process that is conducive to using scientific evidence as the basis for decision making are essential for managing the diffusion of complex and costly diagnostic technologies in patient care.
引用
收藏
页码:149 / 154
页数:6
相关论文
共 22 条
[1]  
ADAMS E, 1998, POSITRON EMISSION TO
[2]  
ADAMS EJ, 1999, POSITRON EMISSION TO
[3]  
ALMAZAN C, 2004, INFORMATIU AATRM, V32, P3
[4]  
Bradbury I, 2002, 2 HLTH TECHN BOARD S
[5]  
*BUND ARZT KRANK, 2002, HLTH TECHN ASS, V39
[6]  
FLYNN K, 1996, POSITRON EMISSION TO
[7]  
*HLTH TECHN BOARD, 2002, 0048 HLTH TECHN BOAR
[8]  
Hojgaard L, 2004, EUR J NUCL MED MOL I, V31, P297, DOI 10.1007/s00259-003-1392-x
[9]   Are Health Technology Assessments a reliable tool in the analysis of the clinical value of PET in oncology? Who audits the auditors? [J].
Hojgaard, L .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (05) :637-641
[10]   Health Technology Assessment of PET in oncology:: re Eur J Nucl Med Mol Imaging 2003; 30:637-641 [J].
Kristensen, FB ;
Adams, E ;
Briones, E ;
Coburn, D ;
Facey, K ;
Hansen, NW ;
Hoeksema, J ;
Morland, B .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (02) :295-297